CJC-1295 vs Ipamorelin
Growth hormone research peptides compared
CJC-1295 is a synthetic GHRH analog that provides sustained GH elevation over days (especially with DAC), while Ipamorelin is a selective ghrelin mimetic that triggers acute pulsatile GH release with minimal cortisol/prolactin impact. CJC-1295 acts on GHRH receptors; Ipamorelin acts on ghrelin receptors. They are often studied together for synergistic GH axis stimulation. Both are sold for laboratory research only.
Research Disclaimer: All content summarizes publicly available preclinical literature. Not for human consumption.
Head-to-Head Comparison
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Classification | GHRH analog (Growth Hormone Releasing Hormone) | Ghrelin mimetic / GH Secretagogue |
| Receptor Target | GHRH receptor (pituitary) | Ghrelin receptor (GHS-R1a) |
| Mechanism | Sustained GHRH signaling → prolonged GH elevation | Pulsatile GH release mimicking natural rhythm |
| Half-Life | With DAC: ~6-8 days; Without DAC: ~30 min | ~2 hours |
| GH Release Pattern | Sustained, elevated baseline | Acute pulse, returns to baseline |
| Cortisol Impact | Minimal | Minimal (highly selective) |
| Prolactin Impact | Low | Very low — major advantage |
| Hunger Stimulation | None | None (unlike GHRP-6) |
| Research Dose Range | 1-2 mg/week (DAC) | 200-300 mcg, 2-3x daily |
| Administration | Subcutaneous, 1-2x weekly | Subcutaneous, 2-3x daily |
| Duration Studied | 8-12 weeks | 8-12 weeks |
| Best For | Sustained GH elevation, IGF-1 increase | Selective GH pulsing, targeted studies |
| Stacking | Commonly paired with Ipamorelin | Commonly paired with CJC-1295 |
When Researchers Choose One vs the Other
CJC-1295 When Studying:
- • Sustained GH/IGF-1 elevation models
- • Long-acting GHRH signaling
- • Less frequent dosing protocols
- • Body composition research
Ipamorelin When Studying:
- • Selective GH pulsing without side hormones
- • Minimal cortisol/prolactin models
- • Natural GH rhythm mimicry
- • Targeted acute GH release studies
Use Both (GH Stack) When:
Research aims for maximum synergistic GH stimulation — sustained baseline (CJC-1295) plus selective pulsing (Ipamorelin). See full GH Stack Guide →
Frequently Asked Questions
Is CJC-1295 or Ipamorelin more effective for GH research?▼
They work through different mechanisms. CJC-1295 provides sustained GH elevation; Ipamorelin provides selective pulsatile release. Most researchers study them in combination for synergistic effects.
What is CJC-1295 without DAC?▼
Also called Mod GRF 1-29, it has a much shorter half-life (~30 minutes vs 6-8 days). It requires more frequent administration but provides more controlled GH pulses.
Does Ipamorelin increase appetite?▼
Unlike GHRP-6, Ipamorelin does not significantly stimulate appetite in preclinical models, making it more selective for GH research.